Luye Pharma: Revenue up 3.5%, profit down 18.4% in H1 2025

For the six months ended 30 June 2025, Luye Pharma Group reported a 3.5% increase in revenue to RMB3,181.1 million, up from RMB3,074.6 million in the same period of 2024. Gross profit also rose by 3.8% to RMB2,157.6 million, with the gross profit margin slightly increasing to 67.8%. Oncology product sales were a significant growth driver, increasing by 13.5% to RMB1,295.2 million. However, cardiovascular system products saw a 9.2% decrease to RMB693.0 million, and alimentary tract and metabolism products decreased by 7.9% to RMB180.2 million.

Despite revenue growth, the group’s net profit decreased by 18.4% to RMB357.4 million, with profit attributable to owners of the parent falling by 19.3% to RMB312.9 million. This was influenced by a 19.7% rise in selling and distribution expenses to RMB1,018.8 million and a 21.9% increase in finance costs to RMB338.5 million, primarily due to higher convertible bonds interest.

The company continues to invest in R&D, with 31 PRC pipeline product candidates and 14 in the U.S., Europe, and Japan. Notable approvals during the period include Zepzelca in China for SCLC and Erzofri in the U.S. for schizophrenia. No interim dividend was proposed for the period.